HIV-1, CD4+ T cells, CD8+ T cells, monocytes, immune exhaustion, immunoregulatory networks, gene regulation, immunological synapse, immunotherapeutic interventions.
In spite of the major progress made in antiviral therapy of HIV (Human Immunodeficiency Virus) infection, there is currently no effective vaccine or therapy capable of eradicating virus or inducing a long lasting viral control after cessation of medication. Such developments are hindered by the limited understanding of protective immunity as well as by mechanisms that lead to ineffective responses in the large majority of HIV-infected individuals.
We are particularly interested in the following areas of investigation:
Identification of molecular mechanisms that control reversible HIV-specific T cells exhaustion.
Investigation of protective components of the CD4+ T helper cell response, in particular in the development of effective antibody responses.
Modulation of the expression of genes regulating the functional plasticity of CD4+ T cells in HIV infection.
Interactions between CD4+ T cells and myelomonocytic subsets.
Regulation of the structure and function of immunological synapses built by T cells in HIV infection.
Impact of anti-PD1 or anti-PD-L1 antibodies in SIV macaque models and in human clinical trials.
We have active collaborations with a broad network of collaborators in Montreal, Canada, the USA, Europe and South Africa.
Visiting Associate Professor, Harvard Medical School, Boston, MA, USA
Associate Member, Broad Institute of MIT and Harvard, Cambridge, MA, USA
Co-Investigator, Canadian HIV Cure Enterprise (CanCURE)
Member, The American Society for Clinical Investigation
Co-investigator, Scripps Center for HIV/AIDS Vaccine Immunology & Immunogen Discovery (CHAVI-ID)